Trial Profile

An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 30 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Modakafusp alfa (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Colon cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Skin cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Takeda; Takeda Oncology

18 Dec 2024 According to ClinicalTrials.gov, this Study was terminated early due to futility
18 Dec 2024 Status changed from completed to discontinued.
12 Dec 2023 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com